Sun Pharma expects normalisation of India business in FY'19

Sun Pharma MD Dilip Shanghvi said the government's enforced price cuts and policy changes are potential risk factors for the business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2DQoHfE
via IFTTT